NCT00410501已完成1 期
An Open Label, Single Dose, Two Period, Single Sequence Crossover Study to Assess the Pharmacokinetic Interaction of QAB149 (300 Mcg Via Inhalation) With Ketoconazole (200 mg Tablet b.i.d.) in Healthy Adult Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of a single 300 µg dose of indacaterol (QAB149) alone administered via inhalation and in the presence of ketoconazole (at steady state) in healthy adult subjects
研究概览
简要总结
This study will evaluate the interaction potential between indacaterol and ketoconazole (a potent CYP3A inhibitor) in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, male or female subjects of Indian origin age 18 to 45 years of age (inclusive)
- •In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation
- •Female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 2 years), or using a double-barrier local contraception if of childbearing potential
- •Body mass index (BMI) within the range of 18.5 to 27 kg/m2 and weigh at least 45 kg for females and 50 kg for males
排除标准
- •Smokers (use of tobacco products in the previous 3 months).
- •Using or planning to use medications affecting GI (gastrointestinal) motility and/or perception (prokinetics, antidiarrheals, antispasmodics, anticholinergics, antacids containing magnesium or aluminum salts, erythromycin, octreotide, ondansetron or other 5-HT3 antagonists).
- •Use of any prescription drugs within 4 weeks prior to dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Paracetamol (up to 4 g daily) is acceptable
- •Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- •Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing or longer if required by local regulation.
- •Significant illness within two weeks prior to dosing.
- •A past medical history of clinically significant ECG abnormalities. Significant history of psychiatric disorder.
- •History of clinically significantfainting, low blood pressure when standing, irregular heart beats or acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or untreated) drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis, nasal polyp or NSAID (non-steroidal anti-inflammatory drug) induced urticaria)
- •A known hypersensitivity or severe adverse event to indacaterol/ketoconazole or drugs similar to the study drugs.
- •History of bowel obstruction, symptomatic gall bladder disease, suspected Sphincter of Oddi dysfunction, or abdominal adhesions.
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
- •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result.
- •Any planned surgery or procedure within 3 months of screening.
- •A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C or VDRL (Venereal Disease Research Laboratory) test result.
- •History of drug or alcohol abuse within the 6 months prior to dosing or evidence of such abuse as indicated by the laboratory assays conducted during the screening or baseline evaluations. Consumption of alcohol within 48 hours of receiving medication.
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Pharmacokinetics of a single 300 µg dose of indacaterol (QAB149) alone administered via inhalation and in the presence of ketoconazole (at steady state) in healthy adult subjects
次要结局
- Safety of a single 300 µg dose of indacaterol (QAB149) given via inhalation in the presence of ketoconazole at steady state in healthy adult subjects.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)NCT00846586Novartis Pharmaceuticals1,134
已完成
3 期
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)NCT00877383Novartis Pharmaceuticals1,142
已完成
1 期
A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult VolunteersHealthy SubjectsPharmacokinetics of YM178NCT01476800Astellas Pharma Inc24
已完成
1 期
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver FunctionHepatic InsufficiencyNCT00416702Novartis32
已完成
1 期
Drug-drug Interaction Study (CKD-501, Ketoconazole)Type 2 Diabetes MellitusNCT01330563Chong Kun Dang Pharmaceutical24